Dehydration polycythemia

Summary

Dehydration polycythemia (MONDO:0002437) is a disease. A subtype of acquired secondary polycythemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	dehydration polycythemia
Mondo ID	MONDO:0002437
DOID	DOID:2833
NCIT	C27310
UMLS	C0856815
MedGen	163544
GARD	0023136
Is cancer (heuristic)	no

Disease family

This is a subtype of acquired secondary polycythemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › immune system disorder › bone marrow disorder › polycythemia › acquired polycythemia › acquired secondary polycythemia › dehydration polycythemia

Related subtypes (3): erythropoietin polycythemia, polycythemia due to hypoxia, Gaisbock syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.